Biotech folks, it's here!! 📚🚀 I'm thrilled to announce that my book, The Biotech Leader’s Handbook is now available on Amazon! If becoming a better leader and building a high-performing team matter to you, this book is for you! You have given my work on biotech leadership

Your defensible moat is your data, not your models. blog.kaleidoscope.bio/your-moat-is-y… A few week ago, we spoke to therapeutics investors about what they diligence with biotech Co's. The value of data repeatedly came up across all stages (Seed-Series B), while AI/ML models did not.

Brad Loncar Totally agree Brad Loncar. Here are a few tips for those looking to partner with various TechBio companies who themselves don't have deep AI expertise to apply to diligence. 1) Look for groups who have significant representation from both bio/chem on their teams as well as

🚀 Exciting News! 🌐 Introducing the AI in Biotech project, a groundbreaking initiative in collaboration with Bits in Bio. 🌟 Spotlight Event: AI in Protein Design Expert Panel 🗓️ Save the Date: Jan 11, 2024, 12pm EST 📌 Register: us06web.zoom.us/webinar/regist…

Asimov Press, a new publishing venture that features writing about biology, launched today. Our magazine and books will cover everything from biosecurity to vaccine development & the long arc of progress in genetic engineering. Learn more & subscribe: press.asimov.com

We're looking to expand our team Sphinx Bio! We're hiring engineers who want to work at the intersection of data, visualizations, LLMs, and science. If you're excited by hard problems with a big impact, please DM me.

Apply to the Genesis Program by Jan 28th, 2024 🙌 Equip yourself with the skills and network to build tomorrow’s life science venture. Apply to one our tracks as a scientific, business, or clinical applicant! 💊 MedTech 🔬 SynBio 🌱 Eco Apply here: bit.ly/48XOAni

Data strategy? There’s a better way to tackle scientific data management for success 📈. Jesse Johnson shares thoughts on our blog about the importance of the “mundane,” why ELNs aren’t enough, how metadata falls off the radar for companies, and more. blog.ganymede.bio/why-data-strat…

My take: most biotechs are not even close to data driven. Jesse Johnson had a great piece on that here: scalingbiotech.substack.com/p/is-biotech-d… Sure, your weekly discovery meeting will look at the most recent experiments to prioritize hits or make go/no go decisions. But being data driven goes

In vivo detox is one of our many active theses. In a polluted world, more emphasis will be put on remediation, both environmental and human (can see this taking off sooner)! Related to this, I have an amazing builder with ML/eng background looking for a biologist

Every biotech struggles with cataloging and tracking its molecules and their experimental results. We wrote a blog post about using Notion to seamlessly design, catalog, and track our programmable molecules (link in next tweet). Great work by Anat Etzion-Fuchs!

Jesse Johnson and I made a ~30 min podcast episode discussing product feature prioritization with unique considerations for Biotech companies. Check it out: open.substack.com/pub/vickysnews…